CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
Adoptive cell therapy with chimeric antigen receptor (CAR) immunotherapy has made
tremendous progress with five CAR T therapies approved by the US Food and Drug …
tremendous progress with five CAR T therapies approved by the US Food and Drug …
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
Therapies with genetically modified T cells that express chimeric antigen receptors (CARs)
specific for CD19 or B cell maturation antigen (BCMA) are approved to treat certain B cell …
specific for CD19 or B cell maturation antigen (BCMA) are approved to treat certain B cell …
CAR-T cell therapy: current limitations and potential strategies
RC Sterner, RM Sterner - Blood cancer journal, 2021 - nature.com
Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary new pillar in cancer
treatment. Although treatment with CAR-T cells has produced remarkable clinical responses …
treatment. Although treatment with CAR-T cells has produced remarkable clinical responses …
Navigating CAR-T cells through the solid-tumour microenvironment
AJ Hou, LC Chen, YY Chen - Nature reviews Drug discovery, 2021 - nature.com
The adoptive transfer of T cells that are engineered to express chimeric antigen receptors
(CARs) has shown remarkable success in treating B cell malignancies but only limited …
(CARs) has shown remarkable success in treating B cell malignancies but only limited …
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
S Rafiq, CS Hackett, RJ Brentjens - Nature reviews Clinical oncology, 2020 - nature.com
T cells genetically engineered to express chimeric antigen receptors (CARs) have proven—
and impressive—therapeutic activity in patients with certain subtypes of B cell leukaemia or …
and impressive—therapeutic activity in patients with certain subtypes of B cell leukaemia or …
Mechanisms of resistance to CAR T cell therapy
NN Shah, TJ Fry - Nature reviews Clinical oncology, 2019 - nature.com
The successes with chimeric antigen receptor (CAR) T cell therapy in early clinical trials
involving patients with pre-B cell acute lymphoblastic leukaemia (ALL) or B cell lymphomas …
involving patients with pre-B cell acute lymphoblastic leukaemia (ALL) or B cell lymphomas …
Clinical lessons learned from the first leg of the CAR T cell journey
RG Majzner, CL Mackall - Nature medicine, 2019 - nature.com
Chimeric antigen receptor (CAR) T cell therapy for B cell malignancies has surpassed
expectations, driving an ever-expanding number of clinical trials and the first US Food and …
expectations, driving an ever-expanding number of clinical trials and the first US Food and …
Tuning the antigen density requirement for CAR T-cell activity
RG Majzner, SP Rietberg, E Sotillo, R Dong… - Cancer discovery, 2020 - AACR
Insufficient reactivity against cells with low antigen density has emerged as an important
cause of chimeric antigen receptor (CAR) T-cell resistance. Little is known about factors that …
cause of chimeric antigen receptor (CAR) T-cell resistance. Little is known about factors that …
Tumor antigen escape from CAR T-cell therapy
RG Majzner, CL Mackall - Cancer discovery, 2018 - AACR
Emerging data from chimeric antigen receptor (CAR) T-cell trials in B-cell malignancies
demonstrate that a common mechanism of resistance to this novel class of therapeutics is …
demonstrate that a common mechanism of resistance to this novel class of therapeutics is …
CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity
BD Choi, X Yu, AP Castano, AA Bouffard… - Nature …, 2019 - nature.com
Chimeric antigen receptor (CAR)-T-cell therapy for solid tumors is limited due to
heterogeneous target antigen expression and outgrowth of tumors lacking the antigen …
heterogeneous target antigen expression and outgrowth of tumors lacking the antigen …